# ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement

- Link: https://www.directorstalkinterviews.com/immupharma-and-avion-pharmaceuticals-sign-exclusive-licence-and-development-agreement/412799285
- Published: 2019-11-28T07:14:24+00:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), a specialist drug discovery and development company,
have announced a licence and development agreement with Avion Pharmaceuticals LLC,
for the exclusive rights to Lupuzor™ in North America (United States). LupuzorTM
is ImmuPharma’s lead compound, a peptide therapeutic and a first-in class autophagy
immunomodulator for systemic lupus erythematosus (SLE or lupus) a potentially life-
threatening auto-immune disease. In addition, Lupuzor™ also has the potential for
treating other auto-immune diseases other than lupus. A trademark licence agreement
also has been signed to allow Avion the use of various trademarks in connection 
with development, manufacture and commercialisation of products under the Licence
and Development Agreement.

**A summary of key highlights to both Agreements**

· Avion and ImmuPharma will co-develop Lupuzor™ to allow registration for marketing
in the US, Europe and elsewhere

· Avion will commercialise Lupuzor™ exclusively for the US.

· ImmuPharma retains all the rights to commercialise Lupuzor™, outside of the US,
either through distribution partnerships or directly by ImmuPharma.

· A new optimised international Phase III trial in lupus patients (which is expected
to include patients in the US, Europe and elsewhere), is targeted to commence in
2020, following agreement of the trial design between Avion, ImmuPharma and the 
US Food & Drug Administration (“FDA”).

· Avion will fund the full expected costs of the new Phase III trial up to $25 million.

· ImmuPharma will receive milestone payments of up to $70 million. A $5 million 
milestone payment will be paid on regulatory approval of Lupuzor™ in lupus, and 
$65 million will be based on achievement of overall sales targets.

· ImmuPharma will also receive $5 million for each additional approval, other than
lupus, as Avion also has the rights, for the US, to explore further opportunities
within Lupuzor™’s peptide platform for other auto-immune indications outside of 
lupus.

· ImmuPharma will receive from Avion tiered double-digit royalties up to 17 percent,
according to pre-specified annual US sales targets.

· Avion has the right to use relevant trademarks for the development, manufacture
and commercialisation of products.

**Background**

ImmuPharma announced top-line trial results from its pivotal Phase III trial of 
Lupuzor™ in lupus patients on 17 April 2018. Further data analysis, reported on 
29 May 2018 demonstrated that in the European cohort (130 patients) Lupuzor™ plus
standard of care (“Active Group”) showed statistically significant reductions (71.1
percent vs 48.8 percent, p=0.0218) in disease activity compared to placebo plus 
standard of care (“Comparator Group”) in 79 patients (60.8 percent) who were anti-
dsDNA autoantibody positive (“Antibody Positive”).

With important insights gained from this pivotal Phase III Lupuzor™ trial, a new
Phase III clinical trial design has been identified. The ability to select the most
responsive patients by biomarker profile has enabled Avion and ImmuPharma to agree
the most robust way forward for Lupuzor™ in lupus patients. The Licence and Development
Agreement allows completion of this new optimised international Phase III trial.
Avion and ImmuPharma have assessed and agreed an expected level of funding required
to complete the Phase III trial, which Avion has agreed to fund in full, in return
for full licensing rights over the drug within the US. ImmuPharma will receive milestone
payments upon achievement of certain milestones, and tiered double-digit royalties
on future revenues generated by Avion.

Outside of lupus, the Licence and Development Agreement also includes the option
for Avion to explore the peptide’s potential in other auto-immune diseases for the
US market.

**Terms of the Agreements**

**Licence and Development Agreement**

The Licence and Development Agreement is between Avion and ImmuPharma (France) S.
A, a subsidiary of the Company.

Avion Pharmaceuticals has licensed the exclusive rights to co-develop, with ImmuPharma,
Lupuzor™ and the molecule forigerimod, to allow registration for marketing in the
US, Europe and elsewhere and for Avion to commercialise Lupuzor™ for US territories.
ImmuPharma retains all rights to commercialise Lupuzor™ outside of the US, either
through distribution partnerships or directly by ImmuPharma. All existing clinical
data and any future joint Intellectual Property will be shared between the two parties
for their respective regions.

Avion has agreed to fund the full costs of the new optimised international Phase
III trial for Lupuzor™ in lupus patients, based on an agreed level of expected costs
up to $25 million. It is anticipated that this new Phase III trial will commence
in 2020, following agreement of the trial design between Avion, ImmuPharma and the
FDA. Following recruitment of patients (to include US, Europe and elsewhere), it
is envisaged that this will be a 52-week trial. Both companies will jointly steer
the clinical program.

ImmuPharma will receive milestone payments of up to $70 million. A $5 million milestone
payment will be paid on regulatory approval of Lupuzor™ in lupus, and $65 million
will be based on achievement of overall sales targets. ImmuPharma will also receive
tiered double-digit royalties up to 17 percent according to pre-specified annual
US sales targets.

Avion will also have the right to explore clinical development for other auto-immune
indications within US territories. Additional milestone payments of $5 million will
be paid to ImmuPharma for each disease indication, outside of lupus, receiving regulatory
approval.

**Trademark Agreement**

The Trademark Agreement is between Avion and ImmuPharma AG, a subsidiary of the 
Company.

The Trademark Agreement allows Avion to use various trademarks in connection with
development, manufacture and commercialisation of products under the Licence and
Development Agreement.

**Centre National de la Recherché Scientifique (“CNRS”)**

The CNRS is the French National Council for Scientific Research and the largest 
basic research organisation in Europe. The CNRS is ImmuPharma’s longstanding collaboration
partner and from which Lupuzor™ was originally licensed. Through this partnership,
CNRS will be entitled to receive from ImmuPharma, low double-digit royalty payments
of monies received by ImmuPharma from Avion through the Licence and Development 
Agreement.

**Avion Pharmaceuticals, LLC**

Established in 2007, Avion is a US-based speciality pharmaceutical company formed
to develop, acquire and market a portfolio of innovative pharmaceutical products
in Women’s Health and other therapeutic categories. Avion has a deep in-house expertise
within medical and regulatory affairs and late-stage clinical development, together
with a strong marketing and commercialisation operation. Avion’s sales team reaches
throughout North America with more than 100 sales representatives with significant
specialist therapeutic experience. Since 2012, Avion has launched more than 55 New
Drug Candidates (NDCs) and 20+ generic product extensions. Avion’s launch earlier
this year of a new gout product (Gloperba®) for adults is an excellent sales and
marketing fit for the future commercialisation of Lupuzor™, as rheumatologists are
the core prescribers and therapeutic influencers in both gout and lupus.

> **Commenting on the Agreements, Dimitri Dimitriou, ImmuPharma’s Chief Executive
> Officer and Robert Zimmer, President & Chief Scientific Officer, said: **
> “We are delighted to be entering into this partnership with Avion, a company which
> has a strong track record within late stage clinical development and commercialisation
> of products within the US, the largest market for lupus patients. Importantly,
> Avion’s specialist sales team is well respected within the rheumatologist community,
> whose focus is on prescribing safe and efficacious treatments for auto-immune 
> diseases such as lupus. This makes it a perfect fit for Lupuzor™. We look forward
> to a long and successful relationship with the Avion team and look forward to 
> sharing updates on progress with shareholders over the next period.”

> **Art Deas, Chief Executive Officer, Avion Pharmaceuticals added: **
> “Avion is extremely pleased to sign this partnership with ImmuPharma. After in-
> depth due-diligence around Lupuzor™, its mechanism of action and learnings within
> the initial Phase III results, we believe that Lupuzor™ has a unique position 
> within lupus that sets it apart from competition, and we are delighted to be extending
> our footprint within this therapeutic area. With approximately 1.5 million patients
> in the US suffering from lupus, there is a significant unmet need for a safe and
> effective drug for this debilitating disease that we believe Lupuzor™ can meet.
> We look forward to forging a strong and successful relationship with ImmuPharma
> going forward.”

Share on:
